{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T04:09:33Z","timestamp":1775966973429,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Given the substantial burden of chronic kidney disease associated with type 2 diabetes, an aggressive approach to treatment is required. Despite the benefits of guideline-directed therapy, there remains a high residual risk of continuing progression of chronic kidney disease and of cardiovascular events. Historically, a linear approach to pharmacologic management of chronic kidney disease has been used, in which drugs are added, then adjusted, optimized, or stopped in a stepwise manner based on their efficacy, toxicity, effects on a patient\u2019s quality of life, and cost. However, there are disadvantages to this approach, which may result in missing a window of opportunity to slow chronic kidney disease progression. Instead, a pillar approach has been proposed to enable earlier treatment that simultaneously targets multiple pathways involved in disease progression. Combination therapy in patients with chronic kidney disease associated with type 2 diabetes is being investigated in several clinical trials. In this article, we discuss current treatment options for patients with chronic kidney disease associated with type 2 diabetes and provide a rationale for tailored combinations of therapies with complementary mechanisms of action to optimize therapy using a pillar-based treatment strategy. [This article includes a plain language summary as an additional file].<\/jats:p>","DOI":"10.1186\/s12882-024-03652-5","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T09:03:13Z","timestamp":1722502993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes"],"prefix":"10.1186","volume":"25","author":[{"given":"Muhammad Shahzeb","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice P.","family":"Lea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"3652_CR1","doi-asserted-by":"crossref","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022 Kidney Int Suppl (2011), 2022. 12(1): pp. 7\u201311.","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"3652_CR2","unstructured":"United States Renal Data System (USRDS). 2022 Annual Data Report. Chronic Kidney Disease: Chap. 1: CKD in the General Population. 2022 09\/06\/2023]; https:\/\/usrds-adr.niddk.nih.gov\/2022\/chronic-kidney-disease\/6-healthcare-expenditures-for-persons-with-ckd."},{"issue":"2 Suppl 2","key":"3652_CR3","first-page":"S12","volume":"49","author":"Kdoqi","year":"2007","unstructured":"Kdoqi. KDOQI Clinical Practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12\u2013154.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"3652_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2215\/CJN.13111215","volume":"11","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, et al. Diabetes, kidney disease, and cardiovascular outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol. 2016;11(8):1384\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"3652_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, et al. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from global burden of Disease 2017. J Diabetes Investig. 2021;12(3):346\u201356.","journal-title":"J Diabetes Investig"},{"key":"3652_CR6","unstructured":"CKDWG, Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314."},{"issue":"11","key":"3652_CR7","doi-asserted-by":"publisher","first-page":"100532","DOI":"10.1016\/j.xkme.2022.100532","volume":"4","author":"CD Mullins","year":"2022","unstructured":"Mullins CD, et al. CKD progression and economic burden in individuals with CKD associated with type 2 diabetes. Kidney Med. 2022;4(11):100532.","journal-title":"Kidney Med"},{"key":"3652_CR8","unstructured":"United States Renal Data System (USRDS). 2022 Annual data report. Chronic Kidney Disease: Chap. 6: Healthcare Expenditures for Persons with CKD. 2022 November 6, 2023]; https:\/\/usrds-adr.niddk.nih.gov\/2022\/chronic-kidney-disease\/6-healthcare-expenditures-for-persons-with-ckd."},{"key":"3652_CR9","unstructured":"United States Renal Data System (USRDS). 2022 Annual data report. End Stage Renal Disease: Chap. 9: Healthcare Expenditures for Persons with ESRD. 2022 November 6, 2023]; https:\/\/usrds-adr.niddk.nih.gov\/2022\/end-stage-renal-disease\/9-healthcare-expenditures-for-persons-with-esrd."},{"issue":"4","key":"3652_CR10","doi-asserted-by":"publisher","first-page":"e002806","DOI":"10.1136\/bmjdrc-2022-002806","volume":"10","author":"JB McGill","year":"2022","unstructured":"McGill JB, et al. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. BMJ Open Diabetes Res Care. 2022;10(4):e002806.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"3652_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","volume":"24","author":"A Chaudhuri","year":"2022","unstructured":"Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab. 2022;24(3):365\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"3652_CR12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"3652_CR13","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"24","key":"3652_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"3652_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"3652_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-Kidney Collaborative Group","year":"2023","unstructured":"The EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"3652_CR17","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dci23-0030","volume":"46","author":"SC Naaman","year":"2023","unstructured":"Naaman SC, Bakris GL. Diabetic Nephropathy: Update on pillars of Therapy slowing progression. Diabetes Care. 2023;46(9):1574\u201386.","journal-title":"Diabetes Care"},{"issue":"5S","key":"3652_CR18","first-page":"S1","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127.","journal-title":"Kidney Int"},{"issue":"5","key":"3652_CR19","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Kidney Int. 2022;102(5):974\u201389.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"3652_CR20","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.2337\/dc24-S011","volume":"47","author":"American Diabetes Association Professional Practice","year":"2024","unstructured":"American Diabetes Association Professional Practice. 11. Chronic kidney Disease and Risk Management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S219\u201330.","journal-title":"Diabetes Care"},{"key":"3652_CR21","unstructured":"US Food and Drug Administration. Farxiga (dapagaflozin) Prescribing Information. 2023 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202293s026lbl.pdf."},{"key":"3652_CR22","unstructured":"US Food and Drug Administration. Invokana (canagliflozin) Prescribing Information. 2023 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204042s034lbl.pdf."},{"key":"3652_CR23","unstructured":"US Food and Drug Adminstration. Jardiance (empagliflozin) Prescribing Information. 2023 November 15, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204629s033lbl.pdf."},{"key":"3652_CR24","unstructured":"US Food and Drug Administration. Victoza (liraglutide) Prescribing Information. 2023 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf."},{"key":"3652_CR25","unstructured":"US Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. 2022 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf."},{"key":"3652_CR26","unstructured":"US Food and Drug Administration. Trulicity (dulaglutide) Prescribing Information. 2022 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s036lbl.pdf."},{"issue":"10","key":"3652_CR27","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"key":"3652_CR28","doi-asserted-by":"crossref","unstructured":"Perkovic V et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med, 2024.","DOI":"10.1056\/NEJMoa2403347"},{"key":"3652_CR29","unstructured":"US Food and Drug Administration. Kerendia (finerenone) Prescribing Information. 2022 August 30, 2023]; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215341s000lbl.pdf."},{"issue":"10424","key":"3652_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379\u201390.","journal-title":"Lancet"},{"issue":"1","key":"3652_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12933-023-01964-8","volume":"22","author":"JD Smeijer","year":"2023","unstructured":"Smeijer JD, et al. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease. Cardiovasc Diabetol. 2023;22(1):251.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3652_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension. 2018;71(4):599\u2013608.","journal-title":"Hypertension"},{"issue":"1","key":"3652_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69\u201378.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"3652_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, et al. Finerenone in Predominantly Advanced CKD and Type 2 diabetes with or without sodium-glucose Cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36\u201345.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"3652_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.14558","volume":"24","author":"P Rossing","year":"2022","unstructured":"Rossing P, et al. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab. 2022;24(1):125\u201334.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"3652_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"19","key":"3652_CR37","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"10193","key":"3652_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"4","key":"3652_CR39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2337\/cd22-0110","volume":"41","author":"J Morales","year":"2023","unstructured":"Morales J, et al. Perspectives on chronic kidney disease with type 2 diabetes and risk management: practical viewpoints and a paradigm shift using a pillar approach. Clin Diabetes. 2023;41(4):553\u201366.","journal-title":"Clin Diabetes"},{"issue":"3","key":"3652_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"},{"key":"3652_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1471-2369-13-133","volume":"13","author":"I Drion","year":"2012","unstructured":"Drion I, et al. Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques. BMC Nephrol. 2012;13:133.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3652_CR42","first-page":"17","volume":"37","author":"P Delanaye","year":"2016","unstructured":"Delanaye P, et al. An age-calibrated definition of chronic kidney disease: rationale and benefits. Clin Biochem Rev. 2016;37(1):17\u201326.","journal-title":"Clin Biochem Rev"},{"issue":"18","key":"3652_CR43","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of Heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"3652_CR44","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"American Diabetes Association Professional Practice","year":"2024","unstructured":"American Diabetes Association Professional Practice. 10. Cardiovascular Disease and Risk Management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S179\u2013218.","journal-title":"Diabetes Care"},{"issue":"3","key":"3652_CR45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","volume":"7","author":"M Provenzano","year":"2022","unstructured":"Provenzano M, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists. Kidney Int Rep. 2022;7(3):436\u201343.","journal-title":"Kidney Int Rep"},{"key":"3652_CR46","doi-asserted-by":"crossref","unstructured":"Meraz-Mu\u00f1oz AY, Weinstein J, Wald R. eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined. Kidney360, 2021. 2(6): p. 1042\u20137.","DOI":"10.34067\/KID.0001172021"},{"issue":"5","key":"3652_CR47","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685\u201393.","journal-title":"Arch Intern Med"},{"issue":"1","key":"3652_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/HYPERTENSIONAHA.118.12060","volume":"73","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma T, et al. Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus. Hypertension. 2019;73(1):84\u201391.","journal-title":"Hypertension"},{"issue":"1","key":"3652_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"3652_CR50","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, et al. Estimated Lifetime Cardiovascular, kidney, and Mortality benefits of Combination Treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with Conventional Care in patients with type 2 diabetes and Albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"issue":"3","key":"3652_CR51","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ekir.2023.12.012","volume":"9","author":"D Kim","year":"2024","unstructured":"Kim D, Perkovic V, Kotwal S. Barriers to care: New medications and CKD. Kidney Int Rep. 2024;9(3):504\u20137.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"3652_CR52","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1053\/j.ajkd.2010.04.021","volume":"56","author":"DE Rifkin","year":"2010","unstructured":"Rifkin DE, et al. Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study. Am J Kidney Dis. 2010;56(3):439\u201346.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"3652_CR53","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ckj\/sfx140","volume":"11","author":"T Mechta Nielsen","year":"2018","unstructured":"Mechta Nielsen T, et al. Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research. Clin Kidney J. 2018;11(4):513\u201327.","journal-title":"Clin Kidney J"},{"issue":"10","key":"3652_CR54","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.2215\/CJN.06960712","volume":"8","author":"O Moranne","year":"2013","unstructured":"Moranne O, et al. Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol. 2013;8(10):1694\u2013701.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"3652_CR55","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/ckj\/sfab243","volume":"15","author":"T Humphrey","year":"2022","unstructured":"Humphrey T, et al. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022;15(4):727\u201337.","journal-title":"Clin Kidney J"},{"key":"3652_CR56","doi-asserted-by":"publisher","first-page":"824095","DOI":"10.3389\/fcvm.2022.824095","volume":"9","author":"E Riccio","year":"2022","unstructured":"Riccio E, et al. RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study. Front Cardiovasc Med. 2022;9:824095.","journal-title":"Front Cardiovasc Med"},{"issue":"20 Suppl","key":"3652_CR57","first-page":"S360","volume":"27","author":"LF Fried","year":"2021","unstructured":"Fried LF, et al. ACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease. Am J Manag Care. 2021;27(20 Suppl):S360\u20138.","journal-title":"Am J Manag Care"},{"issue":"10","key":"3652_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"3652_CR59","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"key":"3652_CR60","unstructured":"US Food and Drug Administration. Aldactone (spironolactone) Prescribing Information. 2018 April 8, 2024]."},{"key":"3652_CR61","unstructured":"US Food and Drug Administration. Inspra (eplerenone) Prescribing Information. 2016 April 8, 2024]."},{"issue":"11","key":"3652_CR62","doi-asserted-by":"publisher","first-page":"e005288","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","volume":"11","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(11):e005288.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"3652_CR63","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","volume":"47","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen NH, et al. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial. Diabetes Metab. 2021;47(4):101190.","journal-title":"Diabetes Metab"},{"issue":"12","key":"3652_CR64","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jchf.2019.08.019","volume":"7","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, et al. Influence of age on efficacy and safety of spironolactone in heart failure. JACC Heart Fail. 2019;7(12):1022\u20138.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"3652_CR65","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152\u201361.","journal-title":"Eur Heart J"},{"issue":"6","key":"3652_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"key":"3652_CR67","unstructured":"Goyal A, Cusick A, Thielemier. B. ACE inhibitors. StatPearls. 2023 September 7, 2023]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430896\/."},{"issue":"6","key":"3652_CR68","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585\u201392.","journal-title":"N Engl J Med"},{"issue":"2","key":"3652_CR69","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MNH.0b013e3283361887","volume":"19","author":"MC Slagman","year":"2010","unstructured":"Slagman MC, Navis G, Laverman GD. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Curr Opin Nephrol Hypertens. 2010;19(2):140\u201352.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"3652_CR70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.matbio.2020.04.005","volume":"91\u201392","author":"M AlQudah","year":"2020","unstructured":"AlQudah M, Hale TM, Czubryt MP. Targeting the renin-angiotensin-aldosterone system in fibrosis. Matrix Biol. 2020;91\u201392:92\u2013108.","journal-title":"Matrix Biol"},{"issue":"1","key":"3652_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/157339911794273973","volume":"7","author":"KN Campbell","year":"2011","unstructured":"Campbell KN, Raij L, Mundel P. Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes. Curr Diabetes Rev. 2011;7(1):3\u20137.","journal-title":"Curr Diabetes Rev"},{"issue":"12","key":"3652_CR72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"3652_CR73","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"3652_CR74","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/17512433.2022.2094770","volume":"15","author":"EV Lerma","year":"2022","unstructured":"Lerma EV, Wilson DJ. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022;15(5):501\u201313.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"3652_CR75","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","volume":"37","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transpl. 2022;37(6):1014\u201323.","journal-title":"Nephrol Dial Transpl"},{"issue":"36","key":"3652_CR76","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem. 2015;290(36):21876\u201389.","journal-title":"J Biol Chem"},{"issue":"5","key":"3652_CR77","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/FJC.0000000000000366","volume":"67","author":"J Grune","year":"2016","unstructured":"Grune J, et al. Steroidal and nonsteroidal mineralocorticoid receptor antagonists cause differential cardiac gene expression in pressure overload-induced cardiac hypertrophy. J Cardiovasc Pharmacol. 2016;67(5):402\u201311.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"8","key":"3652_CR78","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2215\/CJN.0000000000000205","volume":"18","author":"X Luo","year":"2023","unstructured":"Luo X, et al. Influence of SGLT2i and RAASi and their combination on risk of hyperkalemia in DKD: a network meta-analysis. Clin J Am Soc Nephrol. 2023;18(8):1019\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3652_CR79","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2337\/dc20-2604","volume":"44","author":"RA Scholtes","year":"2021","unstructured":"Scholtes RA, et al. Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT trial. Diabetes Care. 2021;44(2):440\u20137.","journal-title":"Diabetes Care"},{"issue":"9","key":"3652_CR80","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3652_CR81","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.2337\/dc20-2265","volume":"44","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, et al. Changes in cardiovascular biomarkers associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes. Diabetes Care. 2021;44(3):e45\u20137.","journal-title":"Diabetes Care"},{"key":"3652_CR82","doi-asserted-by":"publisher","first-page":"110161","DOI":"10.1016\/j.diabres.2022.110161","volume":"194","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, et al. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;194:110161.","journal-title":"Diabetes Res Clin Pract"},{"key":"3652_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/IJNRD.S401623","volume":"16","author":"T Bjune","year":"2023","unstructured":"Bjune T, et al. Hyperkalemia and the use of new potassium binders a single center experience from Vestfold Norway (the PotBind Study). Int J Nephrol Renovasc Dis. 2023;16:73\u201382.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"10","key":"3652_CR84","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","volume":"28","author":"L Blonde","year":"2022","unstructured":"Blonde L, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan\u20132022 update. Endocr Pract. 2022;28(10):923\u20131049.","journal-title":"Endocr Pract"},{"key":"3652_CR85","unstructured":"Greenwalt L. IQVIA: Inequalities in Access to Treatment for Type 2 Diabetes Patients with Chronic Kidney Disease. 2022 8 April, 2024]."},{"issue":"1","key":"3652_CR86","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-020-01154-w","volume":"19","author":"G Schernthaner","year":"2020","unstructured":"Schernthaner G, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):185.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3652_CR87","doi-asserted-by":"publisher","first-page":"108411","DOI":"10.1016\/j.jdiacomp.2023.108411","volume":"37","author":"NR Desai","year":"2023","unstructured":"Desai NR, et al. Design and rationale of FINE-REAL: a prospective study of finerenone in clinical practice. J Diabetes Complications. 2023;37(4):108411.","journal-title":"J Diabetes Complications"},{"issue":"10","key":"3652_CR88","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"2","key":"3652_CR89","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215\u201325.","journal-title":"Diabetologia"},{"issue":"6","key":"3652_CR90","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1053\/j.ajkd.2017.10.026","volume":"71","author":"K Umanath","year":"2018","unstructured":"Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. Am J Kidney Dis. 2018;71(6):884\u201395.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3652_CR91","first-page":"e33509","volume":"15","author":"F de Simoes","year":"2023","unstructured":"de Simoes F, et al. Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) cross-sectional study. Cureus. 2023;15(1):e33509.","journal-title":"Cureus"},{"issue":"1","key":"3652_CR92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2022.3839","volume":"8","author":"MG Nanna","year":"2023","unstructured":"Nanna MG, et al. Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice. JAMA Cardiol. 2023;8(1):89\u201395.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"3652_CR93","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12882-021-02381-3","volume":"22","author":"SJ Jeong","year":"2021","unstructured":"Jeong SJ, et al. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol. 2021;22(1):177.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3652_CR94","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1210\/jc.2005-1093","volume":"90","author":"F Fehse","year":"2005","unstructured":"Fehse F, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(11):5991\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"3652_CR95","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","volume":"1307","author":"DB Maselli","year":"2021","unstructured":"Maselli DB, Camilleri M. Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol. 2021;1307:171\u201392.","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"3652_CR96","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.2337\/db14-0849","volume":"63","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186\u201396.","journal-title":"Diabetes"},{"key":"3652_CR97","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsboll","year":"2012","unstructured":"Vilsboll T, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.","journal-title":"BMJ"},{"issue":"4","key":"3652_CR98","doi-asserted-by":"publisher","first-page":"496","DOI":"10.2337\/db22-0696","volume":"72","author":"A Nguyen","year":"2023","unstructured":"Nguyen A, et al. Association between obesity and chronic kidney disease: multivariable mendelian randomization analysis and observational data from a bariatric surgery cohort. Diabetes. 2023;72(4):496\u2013510.","journal-title":"Diabetes"},{"issue":"17","key":"3652_CR99","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022\u201331.","journal-title":"Circulation"},{"issue":"11","key":"3652_CR100","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.2215\/CJN.02690320","volume":"15","author":"J Li","year":"2020","unstructured":"Li J, et al. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(11):1678\u201388.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03652-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03652-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T09:08:03Z","timestamp":1722503283000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03652-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3652"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03652-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Muhammad Shahzeb Khan and Janice Lea are both Bayer advisory board members.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"248"}}